Skip to main content
. Author manuscript; available in PMC: 2019 Aug 7.
Published in final edited form as: Recent Pat Endocr Metab Immune Drug Discov. 2017;10(2):76–84. doi: 10.2174/1872214810666161020154905

Fig. (2).

Fig. (2).

Proposed model for ROS-dependent activation of MAPKs: Low-levels of ROS activate proliferative ERK signaling under the regulatory control of Ras, while increased levels of ROS lead to Rac1-induced activation of apoptotic JNK1/2 and p38MAPK pathways. [Modified from Lee HS, et al. Ref. 29]. (The color version of the figure is available in the electronic copy of the article).